Transitioning After the COVID-19 Public Health Emergency: Infection Prevention & Control (IPC) Implications

April 27, 2023





#### Making Health Care Better Together

### About Alliant Health Solutions



## Swati Gaur, MD, MBA, CMD, AGSF

#### MEDICAL DIRECTOR, POST-ACUTE CARE NORTHEAST GEORGIA HEALTH SYSTEM

Swati Gaur MD MBA CMD AGSF is the chief medical officer for Senior Care Office and chief executive officer for Care Advances Thru Technology, advancing innovations in geriatric care. She is also the medical director for post-acute care at Northeast Georgia Health System. She is also a medical director for Alliant Health Solutions, a CMS Quality Improvement Organization. She is a member of the Georgia Strike and Support Team with the Georgia Department of Public Health and the University of Georgia.

She has authored several articles related to infection issues such as UTI, Immunization, COVID-19, advanced care planning, and culture change in PALTC. She was commended by AGS for her role on the Health Systems Innovation Committee in 2015. She was named the Medical Director of the Year for 2022-23.



## Erica Umeakunne, MSN, MPH, APRN, CIC

#### **INFECTION PREVENTION SPECIALIST**

Erica Umeakunne is an adult-gerontology nurse practitioner and infection preventionist with experience in primary care, critical care, health care administration and public health.

She previously served as the interim hospital epidemiology director for a large health care system in Atlanta and as a nurse consultant in the Centers for Disease Control and Prevention's (CDC) Division of Healthcare Quality Promotion. While at the CDC, she served as an infection prevention and control (IPC) subject matter expert for domestic and international IPC initiatives and emergency responses, including Ebola outbreaks and, most recently, the COVID-19 pandemic.

Erica enjoys reading, traveling, family time and outdoor activities.

Contact: <a href="mailto:Erica.Umeakunne@allianthealth.org">Erica.Umeakunne@allianthealth.org</a>



## **Objectives**

- Provide an update on COVID-19 epidemiology
- Review the updated COVID-19 vaccine recommendations
- Discuss the end of the public health emergency and relevant policies
- Highlight infection prevention and control (IPC) lessons learned and strategies to prevent COVID-19 and other infections in nursing facilities
- Share Alliant Health Solutions resources to support COVID-19 IPC activities



### **COVID-19 Cases & Deaths**



https://covid.cdc.gov/covid-data-tracker/#trends\_weeklycases\_7daydeathsper100k\_00



### Wastewater COVID-19 Surveillance



https://covid.cdc.gov/covid-data-tracker/#wastewater-surveillance



# Confirmed COVID-19 Cases among Staff and Rate per 1,000 Resident-Weeks in Nursing Homes, by Week—United States







#### Weighted and Nowcast Estimates in United States for Weeks of 1/8/2023 – Nowcast Estim 4/15/2023 – for 4/9/2023 –

#### Nowcast Estimates in United States for 4/9/2023 – 4/15/2023

Hover over (or tap in mobile) any lineage of interest to see the amount of uncertainty in that lineage's estimate.

କ



Nowca	et.		USA										
Model- project	based		WHO label	Lineage #	tal 95%PI								
of varia	ant	innates	Omicron	XBB.1.5	VOC	78.0%	73.6-81.8%						
proport	lions			XBB.1.16	VOC	7.2% 6.5%	4.5-11.3%						
				XBB.1.9.1	VOC		4.8-8.8%						
		XBB.1.5		XBB.1.9.2	VOC	2.5%	1.5-4.1%						
				XBB.1.5.1	VOC	2.4%	1.8-3.1%						
				FD.2	VOC		0.9-3.2%						
				BQ.1.1	VOC		0.6-1.5%						
vo.	XBB.1.5			CH.1.1	VOC	0.3%	0.2-0.5%						
XBB.1.6				XBB	VOC	0.3%	0.2-0.3%						
2				BQ.1	VOC	0.1%	0.1-0.2%						
				BN.1	VOC	0.0%	0.0-0.0%						
				BA.5	VOC	0.0%	0.0-0.0%						
				BA.2.75	VOC	0.0%	0.0-0.0%						
				BF.7	VOC	0.0%	0.0-0.0%						
				BA.2	VOC	0.0%	0.0-0.0%						
				BA.1.1	VOC	0.0%	0.0-0.0%						
41123	48/23	8		BA.5.2.6	VOC	0.0%	0.0-0.0%						
4	8	4/15/23		BF.11	VOC	0.0%	0.0-0.0%						
		2.4		B.1.1.529	VOC	0.0%	0.0-0.0%						
		Selected Week		BA.4.6	VOC	0.0%	0.0-0.0%						
		35	Other	Other*		0.1%	0.0-0.1%						

https://covid.cdc.gov/covid-data-tracker/#variant-proportions





## COVID-19 Vaccine Update



FDA/CDC simplifies COVID-19 vaccine recommendations, allows older adults and immunocompromised adults to get a second dose of the updated vaccine

<u>FDA Press release April 18<sup>th</sup>, 2023</u> <u>CDC Media Statement April 19<sup>th</sup>, 2023</u>

- Monovalent (original) mRNA COVID-19 vaccines will no longer be recommended for use in the United States.
- Alternatives to mRNA COVID-19 vaccines remain available for people who cannot or will not receive an mRNA vaccine. CDC's recommendations for (monovalent) Novavax or Johnson & Johnson's Janssen COVID-19 vaccines were not affected by the changes made today.



New recommendations for people aged ≥6 years without immunocompromise who have not yet received a bivalent mRNA dose





New recommendations for people aged ≥6 years without immunocompromise who have not yet received a bivalent mRNA dose, regardless of COVID-19 vaccination history





### New recommendations for aged ≥6 years without immunocompromise who have already received a bivalent mRNA dose



Vaccination is complete. No doses are indicated at this time.



Flexible for people at higher risk of severe COVID-19: People aged ≥65 years who have not yet received a bivalent mRNA dose









FDA/CDC simplifies COVID-19 vaccine recommendations, allows older adults and immunocompromised adults to get a second dose of the updated vaccine

- How does this change the definition of "up to date" with COVID-19 vaccination?
- Continue to check CDC and CMS websites for updates
  - <u>https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19/vaccines-us.html</u>
  - o <u>https://www.cdc.gov/nhsn/ltc/covid19/index.html</u>
  - o <u>https://www.cms.gov/covidvax-provider</u>







# COVID-19 Emergency Response Transition



#### Public Health Emergency (PHE)

- Initially declared in January 2020
- Ends May 11, 2023
- Coverage, costs, and payment for COVID-19 testing, treatments, and vaccines
- Medicaid coverage and federal match rates
- •Telehealth (extended by the Consolidated Appropriations Act until the end of 2024)

#### National Emergency Declaration

- Issued in March 2020
- Ends May 11, 2023
- Private insurance coverage flexibilities

Emergency Declaration by Health & Human Services

- Initially declared in February 2020
- Allows EUA for medical interventions (vaccines, drugs)
- Stays in effect until terminated by the HHS Secretary; no current end date



### COVID-19 Public Health Emergency (PHE): What is NOT Affected

Access to COVID-19 vaccinations and certain treatments, such as Paxlovid and Lagevrio

FDA's EUAs for COVID-19 products (including tests, vaccines, and treatments)

Major Medicare telehealth flexibilities

Medicaid telehealth flexibilities

Process for states to begin eligibility redeterminations for Medicaid

Access to opioid use disorder treatment



## COVID-19 Public Health Emergency (PHE): What IS Affected

Certain Medicare and Medicaid waivers and broad flexibilities for health care providers

Coverage for free, over-the-counter COVID-19 testing

Reporting of COVID-19 laboratory results and (state) immunization data to CDC

FDA's ability to detect early shortages of critical devices related to COVID-19

Public Readiness and Emergency Preparedness (PREP) Act liability protections

Dispense of controlled substances via telemedicine without an in-person interaction



### COVID-19 Emergency Response Transition: Implications for Infection Prevention & Control

COVID-19 Data Reporting

Vaccination Requirements

Testing & Outbreak investigations

COVID-19 Infection Prevention & Control (IPC) Practices





## COVID-19 Emergency Response Updates: Data Reporting



## COVID-19 Emergency Response Updates: CDC Data Tracking

- Focus on sustainable national COVID-19
   surveillance
- Continue to use all available resources to <u>track</u> <u>COVID-19</u> and monitor its long-term effect on the United States and globally.
  - o Variant data
  - Best ways to protect yourself and others from COVID-19 remain the same, regardless of which lineage causes infection.
  - CDC to monitor changes and continue to communicate about their potential impact.



#### Moving Forward with COVID-19 Data

CDC launched <u>COVID Data Tracker</u> in 2020 to provide state and local public health officials and communities with the COVID-19 data they need in one consolidated, easy-to-use location. Over the past three years, COVID Data Tracker has grown to incorporate county, state, national, and global data streams into more than 70 webpages of key pandemic-related information.



https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html?ACSTrackingID=USCDC\_2145-DM103467&ACSTrackingLabel=4.14.2023%20-%20COVID-19%20Data%20Tracker%20Weekly%20Review&deliveryName=USCDC\_2145-DM103467



## National Healthcare Safety Network (NHSN) Updates: COVID-19 Surveillance Pathways For Data Reporting

- COVID-19 Reporting requirement (implemented May 2020 by CMS Interim Final Rule)
- Nursing homes continue to report <u>COVID-19 data (except for</u> <u>COVID-19 vaccination status)</u> to NHSN through **December 31, 2024**, unless CMS takes regulatory action
- <u>COVID-19 Vaccination status</u> reporting continues through **May 2024** or until CMS declares otherwise



## National Healthcare Safety Network (NHSN) Updates: COVID-19 Surveillance Pathways For Data Reporting

The COVID-19 Module Surveillance Pathways will undergo updates in response to the end of the Public Health Emergency, including:

- Reducing vaccination elements to include only up to date status for residents with a positive COVID-19 test
- Removal of influenza and staffing and supply shortages data fields
- Removal of deaths in the Staff and Personnel Impact Pathway
- Removal of the therapeutics pathway
- Addition of a new data field, hospitalizations, in the Resident Impact and Facility Capacity Pathway to assess relevant outcome data on residents with a positive COVID-19 test



Upcoming NHSN Webinars tentatively scheduled:

June 1, 2023

June 7, 2023

Contact <u>NHSN@cdc.gov</u> for more information.







## COVID-19 Emergency Response Updates: COVID Vaccination Program



### End of the Public Health Emergency on May 11, 2023 and the COVID-19 Vaccination Program

#### What <u>will</u> change

- Possible reduced submission of vaccine administration data from some jurisdictions which may limit completeness of administration data on a national level
- Most jurisdictions have signed a COVID-19 vaccine Data Use Agreement extension through the end of 2023



### End of the Public Health Emergency on May 11, 2023 and the COVID-19 Vaccination Program

#### What will <u>not</u> change

- CDC working with public and private partners to learn more about the short- and long-term health effects associated with COVID-19, who is affected, and why – and implementing vaccine recommendations to optimize protection
- FDA's EUAs for COVID-19 products (including vaccines)
- All vaccines purchased by the U.S. government will continue to be distributed and available for free

#### Public Health Emergency ending ≠ Commercialization



## COVID-19 Emergency Response Updates: Vaccination Education & Access Requirements

- CMS implemented an interim final rule in May 2021 that required nursing homes to educate staff and residents on the risks and benefits of COVID-19 vaccination and to offer or assist in accessing COVID-19 vaccination for staff and residents.
  - As this rule did not include an applicability end date, these requirements will not end with the expiration of the PHE.
  - Nursing homes must continue to educate and offer COVID-19 vaccination to staff and residents beyond the end of the PHE as part of the Requirements of Participation through May 2024 or until otherwise specified by CMS.



## COVID-19 Emergency Response Updates: Vaccination Mandate for Health Care Personnel

- In November 2021, CMS implemented an interim final rule requiring staff, including volunteers, in most Medicare- and Medicaid-certified settings to complete the primary series of COVID-19 vaccination or be granted an approved exemption to work in or provide services on behalf of the certified setting.
  - Federal vaccination mandate remains in effect
    - Bills proposed by Congress to eliminate vaccine requirement
    - Changes may come based on FDA/CDC decisions on future vaccines
    - $\circ$   $\,$  No expiration date at this time; remains in effect





## COVID-19 Emergency Response Updates: Testing & Outbreak Requirements



## **COVID-19 Screening & Testing Requirements**

Admission Screening	<ul> <li>No Change</li> <li>Screening upon admission is recommended for facilities in counties where <u>transmission levels</u> are high.</li> </ul>					
Staff Screening	<ul> <li>No change</li> <li>Screening testing of asymptomatic HCP is at the discretion of the health care facility.</li> </ul>					
Exposure/Close Contact	<ul> <li>No change</li> <li>Asymptomatic patients/residents with close contact with someone with SARS-CoV-2 infection should have a series of three viral tests for SARS-CoV-2 infection</li> </ul>					
Outbreak Investigations	<ul> <li>No change</li> <li>Upon identification of a single new case of COVID-19 infection in any staff or residents, testing should begin immediately (but not earlier than 24 hours after the exposure, if known</li> </ul>					



### **COVID-19 Outbreak Investigation**

#### CDC guidance:

 Perform testing for all residents and HCPs identified as close contacts or on the affected unit(s) if using a broad-based approach, regardless of vaccination status

#### CMS guidance

- Upon identification of a single new case of COVID-19 infection in any staff or residents, testing should begin immediately (but not earlier than 24 hours after the exposure, if known).
  - Table 1: Testing Summary (see image)

Table 1: Testing Summary										
Testing Trigger	Staff	Residents								
Symptomatic individual identified	Staff, regardless of vaccination status, with signs or symptoms must be tested.	Residents, regardless of vaccination status, with signs or symptoms must be tested.								
Newly identified COVID- 19 positive staff or resident in a facility that can identify close contacts	Test all staff, regardless of vaccination status, that had a higher-risk exposure with a COVID-19 positive individual.	Test all residents, regardless of vaccination status, that had close contact with a COVID-19 positive individual.								
Newly identified COVID- 19 positive staff or resident in a facility that is unable to identify close contacts	Test all staff, regardless of vaccination status, facility- wide or at a group level if staff are assigned to a specific location where the new case occurred (e.g., unit, floor, or other specific area(s) of the facility).	Test all residents, regardless of vaccination status, facility-wide or at a group level (e.g., unit, floor, or other specific area(s) of the facility).								
Routine testing	Not generally recommended	Not generally recommended								





https://www.youtube.com/watch?v=ytYZdLA4qU0

https://quality.allianthealth.org/wp-content/uploads/2023/02/Boost-Event-Boosting-IPC-Basics-Feb-2023\_FINAL\_508.pdf





## COVID-19 Emergency Response Updates: Infection Prevention & Control Practices



### **COVID-19 IPC Practices Continue**

Source control / Respiratory etiquette/ Hand hygiene

Personal protective equipment (PPE) use (N95 respirator or surgical mask, goggles, etc.)

Empiric use of transmission-based precautions for asymptomatic resident (contacts)

Early screening, testing, isolation, and work restrictions

Increased frequency environmental cleaning (communal areas, high touch, etc.)

Cohort residents, re-establishing COVID-19 unit

Appropriate vaccinations, therapeutics, and treatments



#### **Transmission Levels**

- Health care settings
- Used on a weekly basis to guide select infection prevention and control actions in a health care setting
- Allows for earlier intervention
- Better protects individuals seeking
   medical care

### COVID-19 Community Levels

- Non-healthcare settings (assisted living facilities, group homes, retirement communities, congregate settings)
- Help individuals and communities decide which prevention actions to take based on the latest information
- Informs individual- and household-level prevention behaviors and community-level prevention strategies for low, medium and high COVID-19 community levels







### Maintain Surveillance: HAI Surveillance & Dashboard

٠

٠



				F	Y2023 (Jai	n-Dec 2025	3)				1					
acility-wide RTIs	January	February	March	April	May	June	July	August	September	October	November	December	FYTD			
otal Respiratory Tract Infections (RTIs)														0		Facility-wide Respiratory Tract Infections (RTIs)
esident Days				1							1		(	0	1.00	
ate (per 1000 resident days)	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!		0.90	
															0.80	
				F	Y2023 (Jai	1-Dec 2023	3)								0.70	
orth Wing RTIs	January	February	March	April	May	June	July	August	September	October	Novembe	December	FYTD		0.60	
otal Respiratory Tract Infections (RTIs)											1		(	0	0.00	
esident Days				1							1		(	0	0.50	
ate (per 1000 resident days)	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!		0.40	
															0.30	
				F	Y2023 (Jai	n-Dec 2023	3)								0.20	
outh Wing RTIs	January	February	March	April	May	June	July	August	September	October	Novembe	December	FYTD		0.10	
otal Respiratory Tract Infections (RTIs)				1							1		(	0	0.10	
esident Days				1									(	0	0.00	
ate (per 1000 resident days)	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!			January February March April May June July August September October November December
																Rate (per 1000 resident days) Linear ( Rate (per 1000 resident days))

A	B	с	D	E	F	G	н	I I	J
						Date of onset or when all	Culture or Lab results (if	Culture or Lab Date of Collection	
Resident Name	<ul> <li>Age *</li> </ul>	Sex *	Current Locatic *	Admission Date	RTI Infection Type	surveillance criteria met 🎽	applicable)	(if applicable)	Comments
									Fever (101.5F), chills, body ache, and new cough noted on
(Example) Jane Doe	72	F	2N	1/1/2023	Influenza-like illness	1/7/2023			1/7/2023

#### AHS HAI Surveillance & Dashboard Tool

- Track and visualize healthcareassociated infections (HAIs)
  - Respiratory tract infections
  - Urinary tract infections
  - o Gastrointestinal tract infections
  - Skin and soft tissue infections
  - Multi-drug resistant organisms (MDRO)
- Track hand Hygiene Compliance
  - Facility-wide
  - Healthcare personnel type
  - Unit or area specific
  - Modifiable spreadsheet (with automated formulas) designed to support nursing facility infection prevention and control (IPC) surveillance
    - o Line lists
    - o Data tables
    - o Graphs



## **Infection Prevention and Control Practices**

- Continue implementing IPC practices for infectious pathogens, including COVID-19 and other respiratory infections
  - <u>Guideline for Isolation Precautions: Preventing Transmission of</u>
     <u>Infectious Agents in Health Care Settings</u>
    - Appendix A
- Use personal protective equipment (PPE) appropriately
- <u>Standard precautions</u> always apply
  - Hand Hygiene
  - Respiratory hygiene/cough etiquette
  - PPE use based on anticipated exposure to blood/body fluids
  - Safe injection practices
  - Cleaning and disinfection
  - Safe linen handling
- Consult with your state or local public health authorities



### CDC COVID-19 Infection Prevention and Control Guidance Resources

Interim IPC Recommendations for Health Care Personnel

Interim Guidance for Managing Health Care Personnel with Infection or Exposure

<u>Strategies to Mitigate Health Care Personnel Staffing Shortages</u>



### Thank You for Your Time! Contact the Patient Safety Team



Amy Ward, MS, BSN, RN, CIC Patient Safety Manager <u>Amy.Ward@AlliantHealth.org</u> 678.527.3653



Paula St. Hill, MPH, A-IPC Technical Advisor, Infection Prevention <u>Paula.StHill@AlliantHealth.org</u> 678.527.3619



Donald Chitanda, MPH, CIC Technical Advisor, Infection Prevention Donald.Chitanda@AlliantHealth.org 678.527.3651



Erica Umeakunne, MSN, MPH, APRN, CIC Infection Prevention Specialist Erica.Umeakunne@AlliantHealth.org







#### Nursing Home and Partnership for Community Health: CMS 12th SOW GOALS







Promote opioid best practices

Reduce opioid adverse drug events in all settings

#### PATIENT SAFETY

Reduce hospitalizations due to c. diff

> . Reduce adverse drug events

Reduce facility acquired infections



#### CHRONIC DISEASE SELF-MANAGEMENT

Increase instances of adequately diagnosed and controlled hypertension

Increase use of cardiac rehabilitation programs

Reduce instances of uncontrolled diabetes

Identify patients at highrisk for kidney disease and improve outcomes

#### CARE COORDINATION

Convene community coalitions

Reduce avoidable readmissions, admissions to hospitals and preventable emergency department visits

Identify and promote optimal care for super utilizers

# COVID-19

Support nursing homes by establishing a safe visitor policy and cohort plan

Provide virtual events to support infection control and prevention

Support nursing homes and community coalitions with emergency preparedness plans

#### IMMUNIZATION

Increase influenza, pneumococcal, and COVID-19 vaccination rates



#### TRAINING

Encourage completion of infection control and prevention trainings by front line clinical and management staff



#### Making Health Care Better Together



#### Julie Kueker Julie.Kueker@AlliantHealth.org Alabama, Florida and Louisiana



Leighann Sauls <u>Leighann.Sauls@AlliantHealth.org</u> Georgia, Kentucky, North Carolina and Tennessee

#### Program Directors



@AlliantQIO



# Making Health Care Better Together



AlliantQIO

This material was prepared by Alliant Health Solutions, a Quality Innovation Network–Quality Improvement Organization (QIN – QIO) under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication No. 12SOW-AHS-QIN-QIOTO1-NH TO1-PCH--3646-04/24/23